CLINICAL NEWS
86 percent, including a complete response
(CR) rate of 51 percent.
“In the setting of relapsed/refractory
CLL, both venetoclax and rituximab can
be given safely at their recommended
single-agent doses (400 mg daily for vene-
toclax and 500 mg/m 2 for rituximab),” Dr.
Seymour told ASH Clinical News. “We do
not need to compromise optimal dosing to
deliver these agents in combination.”
The M13-365 study included adult
patients with relapsed/refractory CLL
or small lymphocytic lymphoma who
had disease that required therapy (per
standard International Workshop on CLL
criteria); an Eastern Cooperative Oncol-
ogy Group performance status score of ≤1;
and adequate marrow, renal, and hepatic
function. Patients were excluded if they
had previously undergone hematopoietic
cell transplantation, had uncontrolled
autoimmune cytopenias, or had any other
“We do not need to compromise
optimal dosing to deliver
[venetoclax and rituximab] in
combination.”
—JOHN F. SEYMOUR, MBBS